Floatz logo

Catequentinib

First-line Targeted Therapy Failure

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the First-line Targeted Therapy Failure cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
CatalYm GmbH
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

Catequentinib is also rated in:

AnlotinibDormant
BB
Indicative ·
71 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
66 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →